Similarly, a radiomic signature was identified that could significantly risk-stratify ALK-positive NSCLC patients (HR 2.181, p < 0.001) when treated with ALK-inhibitor critzotinib [63]. This evidence concerns the gene ALK and non-small cell lung carcinoma.